New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2013
09:10 EDTSTEMStemCells launches Alzheimer's program, received first disbursement of $3.8M
StemCells announced that it has formally launched its Alzheimer's disease program, which is being supported by the California Institute for Regenerative Medicine, or CIRM. The goal of the project is to file, within four years, an Investigational New Drug, or IND, application with the FDA to evaluate the company's proprietary HuCNS-SC product candidate as a potential therapeutic in the treatment of Alzheimer's disease. CIRM has agreed to provide approximately $19.3M to the company in the form of a forgivable loan to help fund preclinical development and IND-enabling activities, and the company recently received an initial disbursement of $3.8M from CIRM. The funding was awarded under CIRM's Disease Team Therapy Development Award program in September 2012.
News For STEM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2015
13:44 EDTSTEMStemCells says patent infringement case against Neuralstem dismissed by court
Subscribe for More Information
07:49 EDTSTEMNeuralstem awarded favorable court ruling in StemCell patent litigation
Subscribe for More Information
July 20, 2015
08:12 EDTSTEMStemCells transplants first patient in clinical trial for macular degeneration
StemCells announced that it has completed transplantation of the first subject in its Radiant Study at the Retina Foundation of the Southwest. The Phase II trial is designed to evaluate both the safety and efficacy of the company's proprietary HuCNS-SC platform technology for the treatment of geographic atrophy, the most advanced form of dry age-related macular degeneration
07:33 EDTSTEMInternational AIDS Society to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use